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Autoantibodies targeting the GABAA receptor (GABAAR) hallmark an autoimmune 
encephalitis presenting with frequent seizures and psychomotor abnormalities. Their 
pathogenic role is still not well-defined, given the common overlap with further autoantibodies 
and the lack of patient derived monoclonal antibodies (mAbs). We cloned and recombinantly 
produced five affinity-maturated GABAAR IgG1 mAbs from cerebrospinal fluid cells, which 
bound to various epitopes involving α1 and γ2 receptor subunits, with variable binding strength 
and partial competition. mAbs selectively reduced GABAergic currents in neuronal cultures 
without causing receptor internalization. Cerebroventricular infusion of GABAAR mAbs and 
Fab fragments into rodents induced a severe phenotype with catatonia, seizures and increased 
mortality, reminiscent of encephalitis patients’ symptoms. Our results prove direct functional 
effects of autoantibodies on GABAARs and provide an animal model for GABAAR encephalitis. 
They further provide the scientific rationale for clinical treatments using antibody depletion and 
pave the way for future antibody-selective immunotherapies. 
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GABAA receptors (GABAARs) are key molecules for physiological brain function, transmitting 
rapid phasic inhibitory synaptic signaling and mediating tonic inhibition at extrasynaptic and 
perisynaptic locations1. The pentameric ligand gated chloride channels can be composed of 
different subunits (α1–6, β1–3, γ1–3, δ, ε, π, θ, and σ1–3), most abundantly in the α1β2γ2 
configuration2. Receptor dysfunction can lead to severe neurological symptoms, such as 
epileptic encephalopathies based on GABAAR subunit mutations
3-6. Recently, cerebrospinal 
fluid (CSF) and serum autoantibodies targeting the α1, β3 and γ2 subunits of GABAARs were 
identified in a new form of autoimmune encephalitis presenting with seizures, refractory status 
epilepticus, cognitive alterations, psychomotor disorders and MRI abnormalities7-10. Patients’ 
sera or CSF containing polyclonal GABAAR antibodies caused downregulation of surface 
GABAAR and electrophysiological changes in cultured neurons
7-9.  
Patients with GABAAR encephalitis frequently harbor further established pathogenic 
autoantibodies such as those targeting LGI1, CASPR2, NMDAR7-9, hence it is unclear whether 
the observed effects exclusively relate to GABAAR antibodies. Interestingly, in a subset of 
patients antibodies against intracellular GAD65 were observed8 and recently strongly expanded 
CD8+ T cell clones have been described11, both pointing towards an accompanying T cell 
driven immune response. 
In this current study, we aimed to characterize the intrathecal human monoclonal antibody 
(mAb) repertoire from antibody-secreting cells (ASCs) and B cells from cerebrospinal fluid in 
acute GABAAR encephalitis. Using recombinant production of CSF derived mAbs
12, 13, we 
generated a set of GABAAR mAbs for the characterization of antibody sequence features, 
epitope mapping and pathogenic functional effects in vitro and in vivo, independent of 
confounding factors. 
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Monoclonal CSF antibodies from encephalitis patient target GABAAR and non- GABAAR 
antigens  
To investigate the functional role of GABAAR antibodies in encephalitis pathogenesis, we first 
explored the monoclonal immunoglobulin repertoire in the CSF of a pediatric GABAAR 
encephalitis patient presenting with catatonia14. The antibody response was captured from 
single cells of three populations: CD138+ ASCs, CD20+CD27+ memory B cells (MBCs) and 
CD20+CD27- non-memory B cells (NMBCs), separated via fluorescence-activated cell sorting 
(Supplementary Fig. 1). Using single cell cloning12, 15, we generated 67 recombinant human 
mAbs, which were screened for GABAAR reactivity on cell-based assays (CBAs) and on 
unfixed murine whole brain sections as an unbiased test for central nervous system (CNS) auto-
reactivity.  
We identified five different human GABAAR mAbs. Four reacted positive in two CBAs using 
human embryonic kidney (HEK) cells expressing either α1β3 (comparable to clinical routine 
assays) or α1β3γ2 GABAARs (Supplementary Fig. 2). In contrast, mAb #113-175 bound to 
GABAARs on the α1β3γ2 CBA only (Supplementary Fig. 2). All five mAbs revealed strong 
tissue reactivity on murine brain sections (Fig. 1a-c, Supplementary Fig. 3), most prominent 
against hippocampal neuropil (Fig. 1a, b), the granule cell and molecular layer in the cerebellum 
(Fig. 1c), putamen and olfactory bulb. Reactivity was confirmed on cultured rat neurons and 
showed clustered distribution of GABAARs along MAP2
+ dendrites (Fig. 1d), overlapping with 
a commercial rabbit GABAAR-α1 antibody and co-localizing with presynaptic vesicular GABA 
transporter (VGAT, Fig. 1e). In addition to typical neuronal GABAAR binding pattern, #113-
201 revealed intense reactivity against choroid plexus and around blood vessels (Supplementary 
Fig. 3g-i).  
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Seventeen of the expressed GABAAR-negative mAbs (27.9%) showed intense tissue binding 
on murine brain sections in distinct patterns, mostly on neuronal surfaces of the hippocampus, 
cerebellum and in basal ganglia, but others also against blood vessels, choroid plexus, 
ependyma and white matter tracts (Fig. 1f-j, Supplementary Fig. 4). A subset also reacted with 
cultured neurons (Fig. 1h-j inserts). Screening for already established neuronal antigens with 
commercial assays identified Homer-3 as the target of #113-212 (Fig. 1j), while the other non-
GABAAR antigens remained unknown. 
 
Polyclonal response to GABAARs derived mainly from IgG1 antibody secreting cells 
We next investigated sequence features of the GABAAR encephalitis immunoglobulin 
repertoire. mAbs derived from different cell populations revealed characteristic Ig isotype 
distributions (Fig. 2a, Supplementary Table 1). All GABAAR mAbs were of the IgG1 subtype 
(Fig. 2b) and derived predominantly from ASCs, also from one MBC, but not from NMBCs 
(Fig. 2c). In contrast, CNS tissue-reactive, but GABAAR-negative mAbs were similarly 
distributed within different cell populations (Supplementary Table 1). Among all mAb 
sequences no clonal relationships were identified, indicating a polyclonal response to 
GABAARs.  
Variable domains from MBC derived mAbs had more somatic hypermutations (SHMs) than 
NMBC derived mAbs on heavy chains, light chains and per mAb in total (22.6 ± 12.8 vs. 10.1 
± 8.6; p=0.0001, ANOVA, posthoc Tukey's multiple comparisons test; Fig. 2d, Supplementary 
Table 1), reflecting affinity maturation. SHM counts of ASC mAbs (14.2 ± 1.9) were between 
those of MBC and NMBC mAbs (Fig. 2d). GABAAR mAbs contained a similar number of 
SHMs as GABAAR-negative mAbs (Fig. 2e). Within GABAAR mAbs SHM were higher in 
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frequency and replacement to silence ratios in complementarity-determining regions (CDR) 
than in frame regions (FR) (Fig. 2f-g), characteristic for antigen driven maturation. 
 
Patient derived mAbs bound α1 and γ2 subunits of GABAAR with different strength and 
partial competition 
To select the most relevant antibodies for functional studies we aimed to characterize the 
subunit specificity and the binding strength of the isolated GABAARs mAbs. To this end, we 
first performed a series of CBAs expressing individual GABAAR subunits or combinations 
thereof. The patient’s polyclonal antibodies from CSF and plasmapheresis eluate (PPE) showed 
predominantly α1 reactivity and additionally bound very weakly to COS7 cells expressing 
α2β3, α5β3 and β3γ2 subunit combinations (PPE only) (Fig. 3a, Supplementary Fig. 5a). mAb 
stainings confirmed the α1 subunit as the main target from GABAAR mAbs (Fig. 3a) and 
excluded binding to α1-5, β1-3 or γ2 subunits for all further mAbs with anti-neuronal reactivity 
(Fig. 3a, exemplarily shown for #113-109). In detail, #113-101, #113-115 and #113-198 
selectively target α1, as these antibodies detected COS7 cells expressing α1β3 and α1β3γ2, but 
not β3 nor γ2 alone (Fig. 3a). Specificity was confirmed by the absence of reactivity to α2β3γ2, 
α3β3γ2, α4β3γ2 and α5β3γ2 (not shown). #113-201 also targeted α1, as it bound to α1β3, but 
not β3 alone and also not to α2β3, α3β3, α4β3 and α5β3 (Fig. 3a, Supplementary Fig. 5b). 
Additionally, #113-201 detected γ2 alone (Fig. 3a), which has about 45% identity with the α1 
subunit. Interestingly, #113-175 bound to α1β3γ2, but neither to α1β3, β3 alone, γ2 alone nor 
to β3γ2 (Fig. 3a), suggesting that #113-175 recognizes a three-dimensional epitope of GABAAR 
heteromers requiring the co-expression of α1 and γ2. Consistently, #113-175 reacted with 
α1β2γ2, but not with α2β3γ2, α3β3γ2, α4β3γ2 and α5β3γ2 (Supplementary Fig. 5c). 
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For the identification of the mAb with strongest binding to natively expressed GABAARs we 
then quantified binding of purified mAbs at serial dilutions to murine cerebellum (Fig. 3b). 
Binding curves were derived from mean fluorescent intensities (MFI) to quantify maximum 
intensities (MFImax) and concentrations at which 50% of MFImax is reached (Half Max; 
Supplementary Table 2). #113-115 showed strongest reactivity (Fig. 3b, red) as indicated by 
lowest Half Max of 160 ng/ml, which was approximately 40-fold higher than from the weakest 
binder #113-201 (Fig. 3b, orange). Models from four out of five mAbs displayed similar 
MFImax. This indicates likewise similar available binding sites, which is for α1-selective mAbs 
represented by the presence of two α1 subunits and therefore two binding sites per 
heteropentameric GABAAR. In contrast, the target epitope of #113-175 involves the α1 and γ2 
subunit, therefore can likely be present only once per GABAAR. Consistently, mAb #113-175 
reached a considerably lower MFImax, but with a similar concentration dependency as #113-115 
(Fig 3b, purple). In a complementary approach using flow cytometry, we found similar mAb 
binding to HEK cells overexpressing α1β3γ2 GABAAR subunits, thus excluding potential bias 
related to unspecific tissue binding (Supplementary Fig. 6a-d).  
As GABAAR binding for all mAbs involves α1, we analyzed whether target epitopes are 
identical or in close proximity in a competition assay. GABAAR mAbs were fluorophore-
coupled and used for quantitative detection of binding to murine cerebellum. The binding of 
each fluorophore-coupled GABAAR mAb was abrogated in the presence of its respective 
unlabeled mAb at excess, but not when co-applied with non-reactive control mAb #mGO53 
(Fig. 3c). Quantification of all possible pairings of GABAAR mAbs revealed that certain mAbs 
can decrease the binding of other GABAAR mAbs (Fig. 3c, black tiles), suggesting competition 
for overlapping target epitopes. In contrast, #113-201 did not influence receptor binding of any 
other GABAAR mAb. Interestingly, the binding signal of #113-101 was markedly increased in 
the presence of unlabeled #113-115 (Fig. 3c, yellow tile) and similarly with #113-115 Fab 
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fragments (Supplementary Fig. 7a). As #113-101 did not directly bind #113-115 
(Supplementary Fig. 7b, c), this finding suggests conformational GABAAR changes induced by 
#113-115 binding, leading to increased #113-101 epitope accessibility.  
 
mAb #113-115 selectively reduced GABAergic currents without causing receptor 
internalization  
Next, we explored the pathogenic relevance of single GABAAR mAbs on GABAergic functions 
in vitro. We selected #113-115 being the mAb with strongest binding to native GABAARs and 
#113-175 which depends on α1γ2-co-expression. In electrophysiological recordings from 
cultured autaptic neurons incubated for 24 hours with 1 µg/ml of #113-175 we observed no 
differences to untreated and control conditions. In contrast, #113-115 led to reduced inhibitory 
postsynaptic signaling as indicated in lower amplitudes of evoked IPSCs (Fig. 4a, c) in 
comparison to untreated condition and to control mAb treatment (#113-115: 0.31 ± 0.09 SEM; 
untreated: 1 ± 0.12, p < 0.0001, Kruskal-Wallis, Dunn’s posthoc; control: 0.91 ± 0.16, p = 
0.0037). This effect was GABA-specific, as amplitudes of selective responses to GABA (Fig. 
4b, d) were likewise reduced (#113-115: 0.55 ± 0.06; untreated: 1 ± 0.09, p = 0.0011; control: 
1.02 ± 0.07, p = 0.0001), whereas responses to kainate and NMDA remained unaffected (Fig. 
4e, f). 
Previous studies using patients’ sera or CSF containing GABAAR antibodies suggested receptor 
internalization as a pathogenic mechanism in GABAAR encephalitis. To examine this 
mechanism at the level of mAbs, we quantified protein levels from neuronal cultures after mAb 
incubation (Supplementary Fig. 8a-c, Fig. 4g-j). The expression levels of GABAAR and control 
protein GluR1 were unaltered under mAb treatment and control conditions, both in the total 
protein (Fig. 4g-h) and in the surface protein fractions (Fig. 4i-j). Surface to total protein ratios 
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of the intracellular marker mortalin were similar in all groups, indicating no mAb influence on 
cell membrane integrity and thus cell viability (Supplementary Fig. 8d). Control experiments 
assured the presence and stability of mAbs after the culture conditions (Supplementary Fig. 8e, 
f). These results were independently confirmed using reader-based immunocytochemistry to 
quantify surface GABAAR levels of neuronal cultures, which displayed no changes between all 
groups (Supplementary Fig. 8g-h).  
 
Cerebroventricular infusion of #113-115 IgG and Fab fragments induced encephalopathic 
symptoms and increased mortality   
The effects observed in vitro indicate direct pathogenicity of antibody-antigen binding, 
independent of receptor internalization, a mechanism related to bivalent antibody mediated 
crosslinking16. Thus, we next assessed whether mAbs can similarly induce pathogenic effects 
in vivo and applied GABAAR mAb #113-115 in mice by continuous cerebroventricular infusion 
via osmotic pumps. To also explore the role of the antibody’s bivalence we generated and 
characterized a monovalent Fab fragment version of #113-115 lacking the Fc domain 
(Supplementary Fig. 9a, b).  
Within a few days after implantation, six out of seven mice of the #113-115 IgG high-dose 
group and all five mice of the #113-115 Fab high-dose group developed encephalopathic 
symptoms compatible with impaired GABAergic inhibition, including myoclonus, twitching, 
gait ataxia and circling (Supplementary Video 1). In the #113-115 IgG low-dose group only 
two out of six mice developed similar symptoms which started later after pump implantation. 
No disease symptoms were observed in the control mice after mAb #mGO53 infusion. All 
symptomatic mice in the #113-115 IgG high-dose and #113-115 Fab group died or had to be 
sacrificed after reaching predefined humane endpoints, commonly status epilepticus (Fig. 5d). 
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Extracted brains from #113-115-infused but not #mGO53-infused mice revealed intense 
deposition of human IgG or Fab in characteristic GABAAR distribution pattern (Fig. 5a-c), 
indicating in vivo antigen binding. However, the levels of GABAAR and control proteins from 
homogenized extracted brains showed no differences between the groups (Fig. 5e-h), consistent 
with the in vitro data (Fig. 4g-j, Supplementary Fig. 8g-h). 
 
GABAAR mAbs caused spontaneous seizures in vivo and spontaneous epileptic activity ex 
vivo 
The mAb-induced in vivo phenotype suggested hyperexcitability and seizures. We used a 
wireless EEG system to further evaluate the influence of GABAAR mAbs on electric activity at 
lower concentrations not causing mortality. We examined twelve male Wistar P21 rats that 
received cerebroventricular infusion of GABAAR mAbs or controls and were concurrently 
implanted with EEG transmitters to record ictal events (Fig. 6a). The EEG coastline length was 
significantly higher in the GABAAR mAb infused animals, indicating increased epileptiform 
activity (Fig. 6b). For the application of #113-115 and also of α1γ2-dependent #113-175, this 
correlated with an increase of ictal events as detected by the automated seizure detection 
program (Fig. 6c, d). The EEG of the GABAAR mAb animals showed significantly higher 
power in all the power band ranges (Fig. 6e).  
After the completion of infusion with GABAAR or control mAbs (day 7-8), acute sagittal brain 
slices were prepared for local field potential recordings to assess for spontaneous epileptic 
activity from electrodes placed in areas CA3 and CA1 of the hippocampus. There were 
significantly higher numbers of spontaneous epileptic events during recordings from the 
GABAAR mAb infused animals compared to controls (Fig. 6f, g). This reaffirms the epileptic 
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activity seen in vivo from depth electrodes within the hippocampus of the GABAAR mAb 
infused animals.  
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Here, we provide insight into the CSF antibody repertoire of acute GABAAR encephalitis. 
Using a recombinant single cell cloning approach, we isolated five monoclonal human 
GABAAR autoantibodies and showed that they recognize GABAARs in vitro and in vivo, induce 
electrophysiological effects independent of receptor internalization and cause a severe 
encephalitic phenotype in two rodent models. Unlike human serum or CSF containing 
polyclonal autoantibodies against GABAAR and potentially other targets, the mAbs allowed the 
detailed analysis of antibody sequences, epitope mapping and autoantibody-specific pathogenic 
functional effects, resulting in a number of novel findings. 
The main epitope of all five mAbs was the α1 receptor subunit, as suggested in previous 
studies8, 9. However, one mAb independently co-detected the γ2 subunit, another bound to a 
shared epitope requiring both α1 and γ2 receptor subunits. Importantly, the latter mAb therefore 
cannot be detected in current commercial cell-based assays which use α1β3 GABAAR, with the 
potential implication that routine diagnostics in acute encephalitis may underestimate disease-
relevant GABAAR antibody titers or even overlook affected patients, in case patients harbor 
only antibodies directed to γ2 receptor subunits in their polyclonal antibody response. The target 
epitopes of some GABAAR mAbs were identical or in close proximity, as shown in our antibody 
competition assays and indicated from prior experiments with the limitations of CSF 
polyclonality8. Conversely, the presence of mAb #113-115 did not reduce, but enhanced 
binding of mAb #113-101 to the GABAAR. This suggests a direct conformational change of 
the receptor upon mAb binding, thus potentially adding a new pathogenic principle to the 
complexity of antibody-induced effects in autoimmune encephalitis. Likewise, conformational 
effects of disease-relevant mAbs may in some cases stabilize the receptor in a specific activation 
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state, similar to nanobodies which in this way allowed first structure crystallography of G 
protein-coupled receptors complexed with their G protein17. 
Our functional investigations in vitro and in vivo showed the pathogenicity of the two selected 
GABAAR mAbs #113-115 and α1γ2-dependent #113-175. Cerebroventricular infusion of both 
mAbs induced a severe phenotype with catatonia, seizures and increased mortality, similar to 
encephalitis patients and in line with epileptic encephalopathies in GABAAR mutation carriers
3-
6. However, electrophysiological recordings from autaptic neuronal cultures revealed a 
reduction of GABAergic currents for mAb #113-115, but not for α1γ2-dependent #113-175. 
The observed increase of epileptiform activity in vivo after #113-175 infusion may possibly be 
mediated via network effects and thus not detectable in the autaptic in vitro model. For both 
mAbs we did not observe receptor internalization, a previously highlighted mechanism7, 9. 
Possible explanations for the different findings include the use of patient samples containing 
polyclonal antibodies with undetermined additional specificities in previous studies and the 
presence of GABAAR β3 subunit antibodies not assessed in our study. For #113-115, the 
electrophysiological findings and missing internalization together with the suggested change of 
receptor conformation indicate direct functional effects upon mAb binding. Possible 
mechanisms include stabilization of the receptor in a desensitized state similar to the GABAAR 
agonist benzamidine18, allosteric modulation of the physiological GABA binding affinity 
and/or neurotransmission efficacy, and orthosteric GABA antagonism. Pathogenic mechanisms 
beyond internalization alone had been suggested by previous results7, showing a frequency 
reduction of IPSCs after GABAAR antibody application. Furthermore, our additional in vivo 
experiments using monovalent GABAAR Fab fragments not only replicated the severe mAb-
induced phenotype, but also supported the concept of direct effects of autoantibody-autoantigen 
binding, similar to recent studies in which Fab fragments of glycine receptor autoantibodies 
specifically reduced glycinergic currents19. In both cases, Fab fragment experiments prove mAb 
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pathogenicity independent of the integrity of the whole antibody; thereby exclude the 
dependency of the antibody’s bivalence and Fc-mediated effector functions such as antibody-
dependent cell-mediated cytotoxicity, antibody dependent cellular phagocytosis and 
complement dependent cytotoxicity.  
GABAAR encephalitis leads to frequent seizures including epilepsia partialis continua and 
treatment-refractory status epilepticus8, 10, which was the predominant phenotype also in our 
animal models. Using wireless EEG in living animals we could quantify epileptiform activity, 
including extended measures such as higher coastline length20 and increased power in the lower 
frequency range (1-4 Hz), consistent with EEG changes in human encephalitis patients21. 
Interestingly, in a pharmacologically induced rodent model of status epilepticus, spontaneous 
seizures were also associated with increased gamma, theta and delta powers in the power 
spectrum similar to our GABAAR mAb model
22. 
Similar to our findings in the related NMDAR encephalitis12, we found a broad spectrum of 
CNS auto-reactivity beyond GABAARs. These mAbs were reactive to surface and intracellular 
epitopes on neurons, endothelium and choroid plexus. For example, we identified one anti-
Homer-3 antibody, a known target protein in some patients with autoimmune cerebellitis and 
ataxia23. Ongoing attempts to identify other auto-antigens using immunoprecipitation/mass 
spectrometry, phage display and protein arrays will likely disclose their relevance for additional 
functional effects, the clinical phenotype and their potential as diagnostic markers. It is tempting 
to speculate that the diverse non-GABAAR mAbs targeting choroid plexus or blood vessels (e.g. 
mAb #113-201) may contribute to blood-brain barrier dysfunction and thus facilitate entrance 
of further antibodies and immune cells into the CNS, similar to the role of GRP78 
autoantibodies in neuromyelitis optica24. 
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The present study confirmed the importance of isolation and detailed characterization of 
disease-specific human mAbs from the CSF of patients with encephalitis to foster the 
comprehensive understanding of humoral CNS autoimmunity. Patient-derived recombinant 
mAbs represent a useful research tool for multiple purposes and thereby allow the detailed 
investigation of disease mechanisms and the translation into animal models to recapitulate the 
clinical phenotype. Most importantly though, retracing the molecular mechanisms of human 
antibody pathogenicity will provide a refined biological view on some important clinical 
conditions such as isolated psychosis or catatonia, which can occur with GABAAR 
antibodies9, 25. This knowledge will help to reduce stigmatization associated with such 
psychiatric conditions by understanding them as autoimmune disorders that may require 
appropriate immunotherapy as a causative treatment in addition to antipsychotics or 
psychotherapy. Simultaneously, the mAbs are the starting point for the development of novel 
diagnostics and highly selective immunotherapies for the growing number of patients with 
antibody-mediated diseases.   
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Patient sample handling 
The index patients’ parents have given written informed consent and analyses were approved 
by the Charité University Hospital Institutional Review Board.  
Four milliliter of CSF were collected during acute phase of encephalitis14 and immediately 
processed for cell pellet cryopreservation, therefore centrifuged for 10 minutes at 400x g, 
supernatant stored at -80°C and the pellet resuspended in 500 µl of 10% dimethyl sulfoxide, 
45% fetal calf serum, 45% RPMI medium before freezing at -80°C. Plasmapheresis eluate was 
collected six days after lumbar puncture and stored at -80°C. 
We used fluorescence-activated cell sorting to isolate single CD138+ ASCs, CD20+CD27+ 
MBCs and CD20+CD27- NMBCs form pre-selected viable CD3-CD14-CD16-DAPI- 
lymphocytes into 96-well PCR plates. The following antibodies were applied: anti-CD3-FITC 
(1:25, Miltenyi Biotec, #130-098-162), anti-CD14-FITC (1:25, Miltenyi Biotec, #130-098-
063), anti-CD16-FITC (1:25, Miltenyi Biotec, #130-098-099), anti-CD20-PerCP-Vio700 
(1:50, Miltenyi Biotec, #130-100-435), anti-CD27-APC-Vio770 (1:12.5, Miltenyi Biotec, 
#130-098-605) and anti-CD138-PE (1:50, Miltenyi, #130-098-122). 
 
Generation of recombinant human monoclonal antibodies  
From single cell cDNA immunoglobulin genes encoding for variable domains of heavy and 
light chains were amplified, sequenced and cloned into expression vectors containing the 
respective constant Ig domains. Sequence analysis data was confirmed by novel custom BASE 
software26. Human embryonic kidney cells (HEK293T) were transiently transfected with an Ig 
vector pair, mAb containing supernatant harvested and Ig concentrations determined, all 
following our established protocols12, 13. 
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For reactivity screenings, supernatants were used if concentration was above 2 µg/ml. For 
detailed characterization of reactivity probabilities and functional assays, cell supernatants were 
purified using Protein G Sepharose beads, as described before12. For Fab fragment synthesis 
(inVivo BioTech, Henningsdorf, Germany) the IgG1 heavy chain vector was modified by the 
deletion of the part encoding for the Fc-domains CH2 and CH3 in exchange for a FLAG-Tag 
and a His-Tag following the amino acids PKSCDKTH of the hinge region. Fab-fragments were 
purified using immobilized metal affinity chromatography (IMAC). 
 
Primary neocortical cell cultures 
Primary P0-P2 neocortical cultures were prepared from WT Wistar rats, as previously 
described27. Briefly, dissected neocortex tissue was dissociated with Papain for 25 min (1.5 
mg/ml; Merck) before trituration in bovine serum albumin (10 mg/ml; Merck). Cells were then 
resuspended in Neurobasal A medium (supplemented with 1x B27, 1x Glutamax, and 100 U/ml 
Penicillin-Streptomycin; Thermo Fisher). Dissociated cells were grown in either 24-well or 6-
well cell culture plates, coated for 1 hour with Poly-L-lysine hydrobromide (20 μg/ml; Merck). 
For imaging with the luminescence plate reader, cells were plated in 500 µl droplets @ 400 
cells / µl (total: 2x105 cells per well of a 24-well plate). For western blot analysis, cells were 
plated in 2 ml droplets @ 500 cells / µl (total: 1x106 cells per well of a 6-well plate). Cultures 
were grown in humidified conditions at 37°C and 5% CO2. Cells were cultured until 20-22 days 
in vitro (DIV) before antibody treatment or fixation.  
 
Immunohistochemistry 
For reactivity screening, recombinant monoclonal antibodies were stained on 20 µm sagittal 
unfixed mouse brain sections mounted on glass slides. After thawing, tissue was rinsed with 
PBS, and then blocking solution (PBS supplemented with 2% Bovine Serum Albumin (Roth) 
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and 5% Normal Goat Serum (Abcam)) was applied for 1 hour at room temperature. As primary 
antibodies, undiluted HEK293T cell supernatants containing recombinant mAbs were 
incubated overnight at 4°C. After washing three times with PBS, Alexa Fluor 488-conjugated 
goat anti-human IgG (1:1,000, Dianova, #109-545-003) diluted in blocking solution was added 
for 2 hours at room temperature, before an additional three time washing and mounting using 
DAPI-containing Fluoroshield. 
For co-stainings, purified recombinant human monoclonal antibodies were used at 5 µg/ml, 
tissue was fixed with 4% paraformaldehyde (PFA) and stained following the same protocol, but 
using blocking solution supplemented with 0.1% Triton X-100 (Chemsolute). For co-stainings 
commercial antibodies rabbit anti-GABAAR α1 (1:250, Abcam, #ab33299), guinea pig anti-
VGAT (1:500, Synaptic Systems, #131004), chicken anti-MAP2 (1:1,000, Thermo Fisher, 
#PA1-16751), rabbit anti-MAP2 (1:1,000, Merck, #AB5622),  Alexa Fluor 568-conjugated 
goat anti-chicken IgG (1:500, Invitrogen, #AB_2534098), Alexa Fluor 647-conjugated goat 
anti-guinea pig IgG (1:1,000, Invitrogen, #A21450), Alexa Fluor 594-conjugated goat anti-
rabbit IgG (1:1,000, Dianova, #111-585-003) were used and stainings examined under an 
inverted fluorescence microscope (Olympus CKX41, Leica DMI6000) or for confocal and 
large-scale tiling images taken with a cooled EMCCD camera (Rolera-MGi PLUS, QImaging). 
 
Cell-based assays 
HEK293T cells were cultured on Poly-L-lysine coated cover slips, transiently co-transfected 
with plasmids (kindly provided from Prof. Kneussel from the Center of Molecular 
Neurobiology in Hamburg, Germany) to express rat α1β3 or α1β3γ2 GABAAR and 48 hours 
later used for live-cell immunostainings following our described protocol, with reduced 
incubation time for primary antibodies to 1 hour at room temperature, followed by PFA fixation.  
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For neuronal stainings, DIV 20-22 live wildtype neocortical rat neurons were stained with 
human mAbs for 1 hour at 4°C, washed once before fixation with methanol for 3 minutes at -
20°C and then co-stained as described above.  
GABAAR-negative mAbs with intense tissue reactivity were screened for established neural 
antigens using commercial panel tests (Euroimmun AG, Lübeck, Germany). 
 
GABAAR subunit reactivity screening 
Cell-based binding assay for GABAAR was described previously.
7 In this study, we additionally 
cloned cDNAs of rat GABAAR 3 (NM_017069), 4 (NM_080587) and 2 (NM_012957) 
from rat brain total RNA by RT-PCR. COS7 cells were transfected with the indicated GABAAR 
subunits. At 24 hour after transfection, the cells were fixed with 2% PFA at room temperature 
for 20 minutes and blocked with PBS containing 10 mg/ml BSA for 15 minutes. The fixed cells 
were incubated with patient derived mAbs (5 g/ml), followed by staining with the Cy3-
conjugated secondary antibody. Then, the cells were permeabilized with 0.1% Triton X-100 for 
10 min, blocked with PBS containing 10 mg/ml BSA, and incubated with antibodies to 
individual GABAAR subunits (underlined subunit in the illustration of Fig. 3a and 
Supplementary Fig. 5), followed by staining with the Alexa488-conjugated secondary antibody. 
We confirmed that any antibodies did not bind to untransfected cells that did not express the 
GABAAR subunits through distinguishing untransfected cells with Hoechst dye (33342, 
Thermo Fisher Scientific) nucleic acid staining. images were captured with a system (LSM5 
Exciter; Carl Zeiss) equipped with a Plan Apochromat 63x/1.40 NA oil immersion objective 
lens.  
The antibodies used in this screening included: rabbit polyclonal antibodies to GABAAR 2 
(1:250, Rockland Immunochemicals, Inc. #600-401-D45), 3 (1:250, extracellular epitope; 
Synaptic Systems #224 303), 5 (1:250, Millipore #AB9678), 3 (1:250, Abcam #ab4046), 
.CC-BY-NC 4.0 International licenseperpetuity. It is made available under a
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in 




and 2 (1:250, extracellular epitope; Synaptic Systems #224 003); guinea pig polyclonal 
antibodies to GABAA receptor 2 (1:250, Synaptic Systems #224 805); and mouse monoclonal 
antibodies to GABAA receptor 1 (1:250, NeuroMab #75-136), 1 (1:250, NeuroMab #75-
137), and 4 (1:250, NeuroMab 73-383). 
The identities of human and rat GABAAR 1, 2, 3, 4, 5, 1, 2, 3 and 2 subunits in 
their amino acid sequence are 100%, 97%, 95%, 89%, 93%, 98%, 99%, 97% and 99%, 
respectively; and that of the human and mouse 2 subunit is 99%, suggesting that the results 
obtained by using rat or mouse GABAAR constructs do not affect the interpretation of our 
results. 
 
Quantification of relative binding strength on murine brain sections 
Following the protocol above, serial dilutions of purified GABAAR mAbs from 50 to 0.002 
µg/ml were used for staining of adjacent unfixed murine brain sections. Cerebellar images were 
recorded with identical settings and analyzed using ImageJ software, version 1.51n (developed 
by the National Institutes of Health). From each image the MFI was determined from 5 random 
regions of interest within granular cell layer, secondary antibody MFI subtracted as background, 
and resulting MFI values scaled to the average MFI values from all five GABAAR mAbs at 20 
µg/ml28. Non-linear regression models (MFI = MFImax * IgG concentration / (Half Max + IgG 
concentration)) under settings for one site specific binding were generated using GraphPad 
Prism 8 (GraphPad Software Inc).  
 
Quantification of relative binding strength via flow cytometry 
Following our established protocol29, HEK293T cells were transiently co-transfected with 
plasmids encoding for rat α1, β3 and γ2 subunits of GABAAR and enhanced green fluorescent 
protein (EGFP) or EGFP only and then stained with serial dilutions of purified mAbs. From 
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live single cells with top 30% protein expression (evaluated by EGFP signal) the MFI of the 
Alexa Fluor 647-conjugated goat anti-human IgG (1:400, Life Technologies) was calculated. 
  
Competition assay  
400 µg of purified GABAAR mAbs were concentrated to a volume of 100 µl using Amicon 
Ultra 100 kDa columns (Merck) and then incubated with 40 µg CruzFluor™ 488 (CF488) 
succinimidyl ester (Santa Cruz Biotechnology) for 1 hour under rotation in the dark. Unbound 
fluorophores were washed out using Amicon Ultra 100 kDa columns. IgG concentrations were 
determined using ELISA and coupling confirmed using UV spectrometry.  
CF488-coupled GABAAR mAbs were used in serial dilutions to stain unfixed mouse sections 
and binding was quantified by MFI quantification of CF488 signals to determine individual 
concentrations for each mAb yielding intensities between detection threshold and signal 
saturation. At these concentrations (0.4 µg/ml for #113-115, 4 µg/ml, for all others), CF488-
coupled mAbs were co-stained with uncoupled mAbs in excess at 50 µg/ml, MFIs quantified 
and compared to single staining MFIs. 
 
Quantification of surface protein expression from cultured neurons 
To quantify expression of cell surface proteins, we performed state-of-the art biotinylation 
assays7, 16. In brief, DIV 20-22 rat neocortical neurons were treated with 5 µg/ml of GABAAR 
or control mAb in culture medium for 16 to 18 hours. Neurons were washed, then incubated 
with EZ-Link Sulfo-NHS-SS-Biotin (Thermo Scientific) for 30 min at 4°C. After quenching 
unbound biotin, scratched neurons were lysed via sonification in RIPA buffer (150 mM NaCl, 
1 mM EDTA, 100 mM Tris HCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, pH 
7.4, supplemented with protease inhibitor cocktail cOmplete™ Mini (Roche)) for 1 hour at 4°C. 
Lysates were cleared of debris by centrifugation at 20,000 × g for 20 minutes. The supernatant 
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(whole protein fraction) was incubated with NeutrAvidin UltraLink beads (Thermo Scientific) 
for 3 hours at 4°C, then eluted (surface proteins fraction). Samples were separated on an 8% 
gel using SDS-PAGE and analyzed by Western blotting. Images were recorded luminescence-
based on ImageQuant® LAS 4000 mini and quantified using ImageQuant TL software (GE 
Healthcare, version 8.2). 
For immunohistochemistry-based receptor quantification we used DIV 20-22 rat neocortical 
neurons cultured in 24-well plates and applied identical mAb treatments as above. Neurons 
were stained as live cells with rabbit anti-GABAAR α1 antibody (1:1000, Abcam, #ab33299), 
then washed, fixed with 4% PFA, before application of IRDye® 680RD goat anti-rabbit IgG 
secondary antibody (1:2000, LI-COR, #925-68071) for 2 hours at room temperature and a final 
washing with PBS. Plates were recorded in an Odyssey CLx Imaging System (LI-COR) under 
high-quality resolution settings and analyzed using Image Studio Ver. 5.2 (LI-COR). For each 
well from a 2000 pixel sized circular region of interest the total pixel intensities were summed, 
background signals from control wells without primary antibody subtracted and these values 
scaled to the mean from all wells under untreated condition of this plate. 
 
Autaptic neurons and electrophysiological recordings 
Autaptic murine striatal neurons (DIV 15‐18) were incubated with 1 µg/ml human GABAAR 
mAb or control antibody (anti-CD52, Bio-Rad, #HCA175) at 37°C for 24 hours. Data collection 
from four independent cultures was performed as previously described30 with the following 
alterations. Cells were recorded in standard intra‐ and extracellular solutions, except for 
chemically induced NMDA responses, measured in extracellular solution containing 0 mM of 
Mg2+, 0.2 mM of CaCl2, and 10 μM of glycine. All drugs were bath applied for 1 second except 
for GABA which was applied for 3 seconds. Currents were normalized per culture to mean of 
untreated recordings.   
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All animal experiments were performed according to the ARRIVE guidelines and were 
approved by the Thuringian state authorities (authorization UKJ-17-053) and UK home office 
guidelines. Male C57BL/6 mice were used at an age of 13-14 weeks and male Wistar rats at 
post-natal age P21 (weighing 50-58g). Animals were housed in temperature and humidity-
controlled conditions on a 12h/12h dark/light cycle and provided with food and water ad 
libitum. 
 
Intrathecal osmotic pump infusions 
An investigator not involved in the animal experiments randomized mice for assignment to the 
respective treatment. Animals either received mAb #113-115 as IgG (high dose group: 500 µg 
over 14 days, 1.5 µg/h, n=7; low dose group: 0.3 µg/h, n=6) or as Fab fragment (equimolar 
(16.5M) to 1.5 µg/h of IgG, n=5) or control mAb mGO53 as IgG (1.5 µg/h, n=5).  
Cerebroventricular infusion with GABAAR mAb or control was performed using osmotic 
pumps (model 1002, Alzet, Cupertino, CA) which were loaded the day before surgery. The 
following characteristics were used as previously reported31, 32: volume 100 µl, flow rate 0.25 
µl/hour, and duration 14 days. For surgery, mice were placed in a stereotaxic frame, and a 
bilateral cannula (model 3280PD-2.0/SP, PlasticsOne) was inserted into the ventricles 
(coordinates: 0.2 mm posterior and ±1.00 mm lateral from bregma, depth 2.2 mm. Each arm of 
the cannula was connected to one osmotic pump, which was subcutaneously implanted on the 
back of the mice (two pumps per animal). After surgery mice were kept single caged and were 
monitored daily to assess symptoms and survival and were videotaped at representative time 
points. Mice were sacrificed at day 15. Brain tissue was obtained and frozen in 2-methylbutane.  
 
.CC-BY-NC 4.0 International licenseperpetuity. It is made available under a
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in 




Quantification of receptor expression from animals treated via osmotic pumps 
For Western blot analysis cryopreserved brain hemisphere from treated mice were thawed and 
dounced in homogenization buffer (1X PBS, 0.32 M Sucrose, 10 mM HEPES pH 7.4, 2 mM 
EDTA, 1.6 mM PMSF, supplemented with protease inhibitor cocktail cOmplete™ Mini). 
Samples were centrifuged at 1,000 x g for 10 minutes. The supernatants (total cell fraction) re-
centrifuged at 10,000 x g for 15 minutes and the obtained supernatant finally ultracentrifuged 
at 100,000 x g for 60 minutes. These pellets were suspended in sample buffer (membrane 
fraction), separated using SDS-Page and analyzed by Western blotting as above. 
 
Rat surgery: placement of ventricular catheters, osmotic pumps and wireless EEG 
transmitters 
Osmotic pumps (model 1007D, Alzet) were used for cerebroventricular infusion of GABAAR 
mAbs (volume 100µl, flow rate 0.5 µl/hour, duration 7 days). The day before surgery, two 
osmotic pumps per animal were prepared by loading with either one mAb or IgG derived from 
one healthy human aged 35 years. As the initial dose of GABAAR #113-115 led to animal death 
through status epilepticus, applied amounts were reduced in subsequent animals, resulting in 
ranges from 40-120 µg human mAb (#113-115: n=3, #113-175: n=3, #mGO53: n=4) or 6 mg 
of polyclonal human IgG (n=2) per animal. The loaded pumps were then connected to 
polyethylene tubing 69mm-x-1.14mm diameter (C312VT; PlasticsOne) and a double osmotic 
pump connector intraventricular cannula (328OPD-3.0/SPC; PlasticsOne). Pumps were left 
overnight in sterile saline solution at 37°C. The next day, under isoflurane anaesthesia, rats 
were placed in a stereotaxic frame for surgery. The osmotic pumps were placed subcutaneously 
and attached cannula was inserted into the lateral ventricles (1.5mm lateral, 0.6mm caudal). A 
subcutaneous pocket was formed over the right flank with a single skin incision and blunt tissue 
dissection for the transmitter (A3028B-DD subcutaneous transmitters, 90-mm leads, 
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OpenSource Instruments (OSI)), and depth electrode (W-Electrode (SCE-W), OSI) placed in 
the left hippocampus (CA3, 3.5mm lateral, 3.6mm caudal, depth 2.3mm) with reference 
electrode implanted in the contralateral skull (3.5mm lateral,  3.6mm caudal).  The cannula and 
skull electrodes were secured with dental cement as previously described33. Placement of 
catheters and electrodes was assessed post mortem during preparation of brain slices for 
electrophysiology and immunostaining. 
 
Collection and analysis of EEG data 
A custom-built Faraday cage with aerial was used to collect and record EEG data. Transmitter 
signals were continuously recorded in animals while freely moving using Neuroarchiver 
software (OSI) and analysed as previously described33, 34. In brief, the EEG coastline length 
was measured as the cumulative absolute difference in voltage between consecutive data 
points35. For automated ictal event detection, video-EEG matching was used to identify ictal 
EEG events. The Event Classifier (OSI) was then used to classify one second segments of EEG 
according to several metrics enabling similar events to cluster together when plotted according 
to metrics. The generated a library of ictal events that allowed fast identification of abnormal 
EEG events by automated comparison to the library 
(http://www.opensourceinstruments.com/Electronics/A3018/Seizure_Detection.html). 
Powerband analysis was carried out using a custom-designed macro.  
 
Local field potential recordings 
At the end of the recording period, 450 μm brain slices were prepared from the GABAAR and 
control mAb infused rats and used for hippocampal local field potential recordings as 
previously described36, 37. Local field potential (LFP) recordings were assessed using Spike2 
software (CED) for spontaneous epileptiform activity. Spike2 was used to calculate the root 
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mean square (RMS) amplitude of each recording. Epileptiform activity was classified as an 
event when it displayed amplitudes greater than four-fold the RMS amplitude, providing the 
event count, while the time difference between these events provided the interevent interval. 
Measurements expressed as median (M), interquartile range (Q1-Q3) and min-max values. 
 
Statistical analysis 
All statistical analysis was conducted using GraphPad Prism 8 (GraphPad Software Inc). For 
sequence analysis numbers of somatic hypermutations were compared using an ordinary one-
way ANOVA test followed by posthoc Tukey's multiple comparisons tests. Amplitudes from 
autaptic neuron recordings were tested using Kruskal-Wallis, Dunn’s posthoc tests. Protein 
expression quantifications from Western blotting and immunohistochemistry data were 
analyzed with ordinary one-way ANOVA tests followed by posthoc Tukey's multiple 
comparisons tests. Kaplan-Meier survival analysis was analyzed by log-rank (Mantel-Cox) test 
followed by ANOVA with posthoc Tukey's multiple comparisons tests. Coastline length 
measurements, ictal event counts and power averages from in vivo EEG recordings and 
interevent intervals of spontaneous ictal activity from post-mortem acute brain slice recordings 
were analyzed using Mann-Whitney tests. 
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Raw data were generated at German Center for Neurodegenerative Diseases (DZNE) Berlin, 
Charité University Medicine Berlin, Aston University Birmingham, University Hospital Jena 
and National Institute for Physiological Sciences Okazaki. All relevant data supporting the key 
findings of this study are available within the article and its Supplementary Information files. 
The mAb sequencing information including raw data files and data derived from custom BASE 
software analysis of all non-GABAAR mAbs from this manuscript have been deposited to Code 
Ocean (https://codeocean.com/capsule/3514767/). Sequencing information for GABAAR 
mAbs will be added to Code Ocean capsule upon publication of the manuscript and will be 
shared from the corresponding authors upon reasonable request during review. 
 
Code availability 
The custom software BASE used for Ig sequence analysis is available at 
https://github.com/automatedSequencing/BASE. 
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Fig. 1 | Binding of human monoclonal antibodies to GABAAR and other CNS targets. (a-
c) Immunofluorescence stainings of human GABAAR mAb #113-115 (green) on unfixed 
murine brain tissue; with binding to (a-b) hippocampal neuropil and (c) in the granule cell 
(GCL) and molecular (MCL) but not Purkinje cell (PCL) layer of the cerebellum, in co-
localization with a commercial anti-GABAAR antibody (red, nuclei in blue). (d-e) 
Immunofluorescence staining on cultured cortical rat neurons, with GABAAR mAb #113-115 
(green) in (d) clustered binding pattern along MAP2+ (red) dendrites and in (e) co-localization 
with commercial antibodies against GABAAR (red) and the pre-synaptic marker vesicular 
GABA transporter (vGAT, blue). (f-j) Immunofluorescence staining of human GABAAR -
negative mAbs (green, nuclei in blue) from encephalitis patient’s CSF repertoire with specific 
brain tissue reactivity in variable distribution patterns, including binding to (f) blood vessels, 
(g) hippocampal neuropil, (h) cell soma in corpus callosum and (i-j) cells of different cerebellar 
layers. Inserts in (h-j) show mAb staining on cultured neurons. Scale bars indicate 100 µm in 
(a-c), 20 µm in (d-e), 100 µm in (f-j) and 20 µm in inserts of (f-j).  
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Fig. 2 | Ig sequence data analysis from GABAAR encephalitis CSF repertoire. (a) Ig 
subclass distributions per mAb source cell type from GABAAR encephalitis CSF repertoire. (b-
c) Absolute frequencies of GABAAR-reactive (GABAAR+) and GABAAR-negative 
(GABAAR-) mAbs per (b) Ig subclass and (c) mAb source cell type. (d) Comparison of SHM 
counts in the variable domain V genes between mAbs of different source cell types (ASC n = 
5, MBC n = 16, NMBC = 46). Data was analyzed using ordinary one-way ANOVA followed 
by posthoc Tukey's multiple comparisons tests (p values not shown when not significant). Bars 
indicate mean ± SD. (e) Comparison of SHM counts in the variable domain V genes between 
GABAAR+ (n = 5) and GABAAR- (n = 62) mAbs. Bars indicate mean ± SD. (f) Relative 
frequencies of SHM per nucleotide within complementarity-determining regions (CDR) and 
frame regions (FR) of GABAAR+ mAb genes, shown as mean ± SEM, n = 5. (g) Ratios of 
replacement to silence (R/S) mutations within CDRs and FRs for all SHM of all GABAAR+ 
mAb genes combined. 
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Fig. 3 | GABAAR subunit epitopes and mAb binding properties. (a) Immunofluorescence 
stainings as cell-based assays (CBA) using COS7 cells overexpressing individual or multiple 
GABAAR subunits (as illustrated in left column) to evaluate subunit-specific binding of 
patient’s polyclonal samples and derived recombinant mAbs (red, nuclei in blue). Negative 
controls #mGO53 and #113-109 showed no binding. Underlined subunits were stained with 
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subunit-specific commercial antibodies (shown in green in image inserts). Note that β3 alone is 
expressed on the cell-surface, but α1 alone is not38. Representative scale bar indicates 20 µm. 
(b) For relative quantification of human GABAAR mAb binding to natively expressed receptors 
the mean fluorescence intensity (MFI) was measured from binding in the granule cell layer of 
the murine cerebellum. Representative images from #113-115 are shown in top row with IgG 
concentrations as indicated. Representative scale bar indicates 100 µm. MFIs from 15 regions 
of interest (ROI) from 3 independent experiments were used to fit non-linear regression models 
of specific binding. Error bars indicate SEM. (c) For analysis of competitive binding, 
fluorophore-coupled GABAAR mAbs (detection mAbs) were stained on murine brain tissue in 
combination with of an uncoupled mAb (competing mAb) in excess. Exemplary images from 
coupled #113-101 are shown in top row with a representative scale bar indicating 100 µm. 
Quantified mean MFIs as relative values to non-competing condition of the respective coupled 
mAb are shown as a heat map, each derived from 45 ROI from 3 independent experiments. 
Receptor binding competition is visualized in black and signal enhancement in yellow.  
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Fig. 4 | mAb #113-115 selectively reduced GABAergic signalling in vitro, independent of 
receptor internalization. (a-b) Representative traces from (a) evoked or (b) GABA-dependent 
currents of murine autaptic neurons after pre-incubation with indicated human mAb. (c-f) 
Amplitudes of (c) evoked or chemically induced responses to (d) GABA, (e) kainate or (f) 
NMDA of murine autaptic neurons after mAb pre-incubation as indicated (values normalized 
to mean of untreated condition, n = 25 per condition). Data was analyzed using Kruskal-Wallis, 
Dunn’s posthoc tests (p values not shown when not significant). (g-j) Quantifications of the 
indicated (g-h) total and and (i-j) biotinylated surface proteins from cultured neocortical rat 
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neurons as analyzed by Western blotting and normalized to N-Cadherin expression and mean 
of untreated condition. Error bars indicate SEM; n = 4 separate cultures. 
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Fig. 5 | GABAAR IgG and Fab induced increased mortality. (a-c) Immunofluorescence 
stainings on brain sections from C57BL/6 mice after cerebroventricular infusion (cv-inf.) of the 
indicated GABAAR or control mAbs over 14 days. Detection with anti-human Fc-specific 
antibody (red) or anti-human Fab-specifc antibody (green, insert in b) revealed characteristic 
hippocampal mAb deposition of (a) #113-115 IgG and (b) #113-115 Fab; (c) not seen in control 
animals receiving control IgG (#mGO53). Representative scale bars indicate 100 µm. (d) 
Kaplan-Meier plot for survival of C57BL/6 mice after cerebroventricular infusion over 14 days 
of indicated mAbs as IgG in high or low dose (1.5/0.3 µg IgG per hour) or as Fab in high dose. 
Survival was significantly different (p = 0.0001, log-rank Mantel-Cox), with increased 
mortality in GABAAR #113-115 IgG high dose (n = 7) and #113-115 Fab high dose (n = 5) 
groups in comparison to #113-115 IgG low dose (n = 7) and control IgG high dose (n = 5) 
groups (ANOVA, posthoc Tukey's multiple comparisons tests; all p ≤ 0.001). (e-h) 
Quantifications of the indicated (e-f) total and and (g-h) surface proteins from murine brain 
homogenates after cerebroventricular mAb infusion as analyzed by Western blotting and 
normalized to mean of control IgG group. Error bars indicate SEM; n = 10 hemispheres per 
group. 
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Fig. 6 | GABAAR mAbs caused spontaneous seizures in vivo and spontaneous epileptic 
activity ex vivo. (a) Representative EEG of an ictal event recorded from a CA3 depth electrode 
of a Wistar rat receiving GABAAR mAb infusion. (b) Comparison of hourly averages of 
coastline length between GABAAR mAb (#113-115 n = 3, #113-175 n = 3) and control (n = 6) 
infused animals (Mann-Whitney). Horizonzal lines indicate mean and quartiles. (c) Comparison 
of the ictal event counts between animals during infusion with GABAAR mAb or control as 
analyzed from Neuroarchiver seizure detection software (Mann-Whitney). Animal numbers as 
in (b). Bars indicate mean median ± SEM. (d) Distribution of the detected ictal event over time. 
(e) Comparison of hourly EEG power averages throughout 7-day recordings during GABAAR 
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mAb or control infusion (Mann-Whitney). Animal numbers as in (c). (f) Local field potential 
recording from the CA3 region in a sagittal brain slice from a rat after GABAAR mAb infusion 
(upper trace) showing spontaneous ictal activity ex vivo, not seen in controls (lower trace). (g) 
Comparison of interevent intervals of spontaneous ictal activity from post-mortem acute brain 
slice recordings from rats after GABAAR mAb (#113-115 n = 4, #113-175 n = 3) or control (n 
= 8) infusion (non-parametric, unpaired Mann-Whitney test). Bars indicate mean ± SEM.  
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